Abstracts Archive - Page 1928 of 2425 - ACR Meeting Abstracts

Abstract Number: 1848 • 2014 ACR/ARHP Annual Meeting
Risk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour-Necrosis Factor Alpha Inhibition
Karen M. Fagerli^1,2, Louise K. Mercer¹, Kath D. Watson¹, Jonathon Packham³, Deborah PM Symmons^4,5, Kimme L. Hyrich⁶ and . On behalf of the BSRBR⁷, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ²Diakonhjemmet Hospital, Oslo, Norway, ³Institute of Science and Technology in Medicine, Keele, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷British Society for Rheumatology, London, United Kingdom
Background/Purpose Few studies have explored risk of cancer in psoriatic arthritis (PsA). There are concerns that the risk may be raised, not only by the…
Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting
Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…
Abstract Number: 1863 • 2014 ACR/ARHP Annual Meeting
CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Pirow Bekker¹, David Jayne², Annette Bruchfeld³, Matthias Schaier⁴, Kazimierz Ciechanowski⁵, Lorraine Harper⁶, Michel Jadoul⁷, Mårten Segelmark⁸, Daina Selga⁹, Istvan Szombati¹⁰, Michael Venning¹¹, Christian Hugo¹², Paul L. van Daele¹³, Ondrej Viklicky¹⁴, Antonia Potarca¹⁵ and Thomas J. Schall¹⁵, ¹Medical & Clinical Affairs, Chemocentryx, Inc., Mountain View, CA, ²Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Pomeranian Medical University, Szczecin, Poland, ⁶Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁷Cliniques Saint-Luc, Brussels, Belgium, ⁸Nephrology, Linkobing University, Linkoping University, Linkoping, Sweden, ⁹Lund University, Lund, Sweden, ¹⁰Budaclinic, Budapest, Hungary, ¹¹Manchester University, Manchester, United Kingdom, ¹²Dresden University, Dresden, Germany, ¹³Erasmus Medical Center, Immunology, Rotterdam, Netherlands, ¹⁴Instit of Clin and Exp Med, Prague, Czech Republic, ¹⁵ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: CCX168 is a potent, specific C5aR inhibitor in clinical development for ANCA-associated vasculitis. The initial focus of this randomized, double-blind, placebo-controlled clinical trial was…
Abstract Number: 1862 • 2014 ACR/ARHP Annual Meeting
The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis
Peter C. Grayson¹, Carmelo Carmona-Rivera¹, Lijing Xu², Noha Lim², Adam Asare², Deborah J. Phippard², Mariana J. Kaplan³, Peter A. Merkel⁴ and Paul A. Monach⁵, ¹NIAMS Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, ²Immune Tolerance Network, Bethesda, MD, ³Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Section of Rheumatology, Vasculitis Center, Boston University School of Medicine, Boston, MA
Background/Purpose: To discover new pathways involved in the pathophysiology of ANCA-associated vasculitis (AAV) and identify potential clinical biomarkers through use of whole-genome gene expression profiling.…
Abstract Number: 1861 • 2014 ACR/ARHP Annual Meeting
The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis
Antoine G. Sreih¹, Rana Ezzeddine², Juan Fan³, Lin Leng³, Simon Carette⁴, David Cuthbertson⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Carol A. Langford⁸, Carol McAlear⁹, Paul Monach¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³, Peter A. Merkel¹⁴ and Richard Bucala¹⁵, ¹Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Biostatistics, Bristol-Myers Squibb, Wallingford, CT, ³Yale University, New Haven, CT, ⁴Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Department of Biostatistics, University of South Florida, Tampa, FL, ⁶Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, St. Joseph’s Hospital, McMaster University, Hamilton, ON, Canada, ⁸Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology, Boston University, Boston, MA, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Frederichs Dr NW, Mayo Clinic, Rochester, MN, ¹³Division of Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁵Rheum/Dept of Int Med, Yale University School of Med, New Haven, CT
Background/Purpose: Macrophage Migration Inhibitory Factor (MIF) is an immunoregulatory cytokine that may play a central role in the pathogenesis of granulomatous diseases. Two functional polymorphisms…
Abstract Number: 1860 • 2014 ACR/ARHP Annual Meeting
Serum Calprotectin and Disease Relapse in ANCA-Associated Vasculitis
Juliana B Draibe¹, Ruth J. Pepper¹, Peter A. Merkel², Alan D. Salama¹ and for The RAVE-ITN Investigators³, ¹Centre for Nephrology, University College London, London, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Immune Tolerance Network, San Franciscco, CA
Background/Purpose: In ANCA-associated vasculitis (AAV) disease relapses remain common but there are no reliable means to predict them. We previously demonstrated that serum calprotectin…
Abstract Number: 1859 • 2014 ACR/ARHP Annual Meeting
Age-Specific Predictors of Mortality in SLE
Dominique Ibanez¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mortality is 3 to 5 times greater in SLE patients then it is in the general population – especially among younger patients where it…
Abstract Number: 1858 • 2014 ACR/ARHP Annual Meeting
Standardized Mortality Ratios for Cause-Specific Deaths in Lupus Patients Followed Prospectively at a Single Centre Lupus Clinic
Barry J. Sheane¹, Dominique Ibanez², Dafna D. Gladman³ and Murray B. Urowitz³, ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Despite the significant improvement in survival rates of patients with systemic lupus erythematosus (SLE) over the last four decades, mortality rates have remained at…
Abstract Number: 1856 • 2014 ACR/ARHP Annual Meeting
National Hospitalization Trends in Lupus Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Infections
Sara G. Murray¹, Gabriela Schmajuk¹, Laura Trupin¹, Lianne S. Gensler² and Jinoos Yazdany¹, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). With changing therapeutic practices over the past 15 years,…
Abstract Number: 1855 • 2014 ACR/ARHP Annual Meeting
Not Keeping up with the Times: High Mortality and Early Death Due to Disease in North American Natives with Systemic Lupus Erythematosus (SLE)
Ripneet Puar¹, Carol A. Hitchon², David B. Robinson³, Hani El-Gabalawy³, Navjot Dhindsa¹ and Christine A. Peschken⁴, ¹Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Canada, Winnipeg, MB, Canada
Background/Purpose: Reports in recent decades show drastic improvements in survival of SLE patients, with 10-15 year survival rates of >90%. However, little is known about…
Abstract Number: 1854 • 2014 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients Have Increased Risk of Short Term Adverse Events after Total Hip Arthroplasty
Jordan Roberts¹, Lisa A. Mandl², Edwin Su³, David J. Mayman⁴, Mark P. Figgie⁴, Arielle Fein⁵, Yuo-Yu Lee⁵, Ummara Shah⁶ and Susan M. Goodman², ¹Weill Cornell Medical College, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedic Surgery, Hospital for Special Surgery, New York, NY, ⁴Orthopedics, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Division of Rheumatology, New York University School of Medicine, NYC, NY
Background/Purpose: Total Hip Arthroplasty (THA) is the most frequent orthopedic procedure performed in lupus (SLE) patients. Whether SLE patients have higher rates of complications after…
Abstract Number: 1852 • 2014 ACR/ARHP Annual Meeting
Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study
Katelynn Wilton¹, Floranne C. Ernste², Cynthia S. Crowson³, Eric L. Matteson⁴, Hilal Maradit Kremers⁵ and Marta Sánchez-Menéndez⁶, ¹Medical Scientist Training Program, Mayo Clinic Rochester, Rochester, MN, ²Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Health Sciences Research, Mayo Clinic, Rochester, MN, ⁶Centro Medico de Asturias, Oviedo, Spain
Background/Purpose: Patients diagnosed with rheumatoid arthritis and psoriatic arthritis (PsA) have an increased risk of multiple comorbidities that predispose them to cardiovascular disease (CVD). Although…
Abstract Number: 1851 • 2014 ACR/ARHP Annual Meeting
Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
Robert Kalb¹, David Fiorentino², Mark Lebwohl³, Craig Leonardi⁴, John Toole⁵, Kavitha Goyal⁶, Steve Calabro⁶, Wayne Langholff⁷ and Steve Fakharzadeh⁸, ¹SUNY at Buffalo, School of Medicine and Biological Sciences, Buffalo, NY, ²Dermatology, Stanford University, Redwood City, CA, ³Mount Sinai Medical Center, New York, NY, ⁴Central Dermatology, St. Louis, MO, ⁵University of Manitoba, Dermadvances Research, Winnipeg, MB, Canada, ⁶Janssen Services, LLC, Horsham, PA, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Janssen Services, LLC, Spring House, PA
Background/Purpose To report the cumulative rates of serious infections in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) study. Methods PSOLAR is a multicenter, longitudinal, observational…
Abstract Number: 1866 • 2014 ACR/ARHP Annual Meeting
Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Debbie Ehrmann Feldman¹, Evelyne Vinet², Sasha Bernatsky³, Ciaran Duffy⁴, Elizabeth Hazel⁵, Marie-Pierre Sylvestre⁶, Garbis Meshefedjian⁷ and Anick Bérard¹, ¹Université de Montréal, Montréal, QC, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ⁴Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁵McGill University Heatlh Center, Montreal, QC, Canada, ⁶médecine sociale et préventive, Université de Montréal, Montréal, QC, Canada, ⁷Public Health Department of Montreal, Montreal, QC, Canada
Background/Purpose: Although there is a higher frequency of adverse birth outcomes in women with rheumatoid arthritis, little is known on the subject regarding women who…
Abstract Number: 1865 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study
Neda Amiri¹, Natasha Dehghan², Eric C. Sayre³, Kamran Shojania¹ and J. Antonio Avina-Zubieta⁴, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose Limited literature is available on the incidence of myocardial infarction (MI) and cerebrovascular accidents (CVA) in patients with Granulomatosis with Polyangiitis (GPA). We assessed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].